Capricor Therapeutics, Inc. (CAPR)
- Previous Close
5.55 - Open
5.52 - Bid 5.03 x 100
- Ask 5.08 x 400
- Day's Range
4.68 - 5.65 - 52 Week Range
2.68 - 8.22 - Volume
929,593 - Avg. Volume
283,293 - Market Cap (intraday)
159.09M - Beta (5Y Monthly) 4.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.83 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.
www.capricor.comRecent News: CAPR
Performance Overview: CAPR
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CAPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CAPR
Valuation Measures
Market Cap
159.09M
Enterprise Value
121.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.37
Price/Book (mrq)
7.04
Enterprise Value/Revenue
4.84
Enterprise Value/EBITDA
-5.30
Financial Highlights
Profitability and Income Statement
Profit Margin
-88.52%
Return on Assets (ttm)
-27.66%
Return on Equity (ttm)
-129.63%
Revenue (ttm)
25.18M
Net Income Avi to Common (ttm)
-22.29M
Diluted EPS (ttm)
-0.83
Balance Sheet and Cash Flow
Total Cash (mrq)
39.49M
Total Debt/Equity (mrq)
9.89%
Levered Free Cash Flow (ttm)
-10.92M